Dare Bioscience, Inc. annual report, FY2022

Dare Bioscience, Inc. — FY2022 Form 10-K

Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a standalone fourth-quarter report; quarterly results are not clearly provided in the filing text. Dare is a clinical-stage biopharmaceutical company focused on women’s health. XACIATO, approved in December 2021 for bacterial vaginosis, was its only FDA-approved product and had not yet launched commercially by year-end.

Financial performance and position

MetricFY2022FY2021
Revenue$10.0 million$0
Research and development expense$30.0 million$30.6 million
General and administrative expense$11.2 million$8.4 million
Total operating expenses$41.4 million$39.1 million
Operating loss$31.4 million$39.1 million
Net loss$30.9 million$38.7 million
Basic and diluted loss per share$0.37$0.63
Net cash used in operating activities$18.1 million$28.8 million
Cash and cash equivalents, year-end$34.7 million$51.7 million

The $10.0 million of FY2022 revenue was the upfront license payment from Organon for XACIATO—not product sales, royalties, or recurring revenue. No gross margin is clearly presented. Other income was $0.4 million, principally interest income; FY2021 included a $0.4 million gain from forgiveness of a Paycheck Protection Program loan.

At December 31, 2022, Dare reported total assets of $43.8 million, current liabilities of $31.6 million, working capital of $11.4 million, and stockholders’ equity of $11.1 million. Deferred grant funding liabilities were $18.3 million; these funds are earmarked for specified development activities. The balance sheet reported lease liabilities of approximately $0.5 million and no outstanding note payable. Accumulated deficit was $141.1 million.

Changes, outlook, and principal risks

  • Revenue increased from zero in 2021 due to the Organon license payment. Net loss narrowed by $7.7 million, while operating expenses rose 6%; lower R&D costs were largely offset by higher G&A and spending on Sildenafil Cream and other clinical-stage programs.
  • Cash declined by $17.0 million during 2022. Financing provided $1.3 million, compared with $75.8 million in 2021, when equity sales were substantially higher. Operating cash use improved year over year, partly reflecting working-capital changes and grant funding.
  • Management stated that existing cash was insufficient for working-capital and other liquidity needs over the 12 months following the financial statements’ issuance, and that additional capital would be needed by mid-2023 if programs proceeded on schedule. The auditor’s report and management both identify substantial doubt about the company’s ability to continue as a going concern. No assurance is given that financing will be available on acceptable terms.
  • Management expected 2023 R&D and G&A expenses to increase. At filing, the company expected XACIATO’s first U.S. commercial sale in the first half of 2023, which would trigger a $2.5 million Organon milestone; future royalties depend on net sales and are outside Dare’s direct control. Organon may terminate the license after June 30, 2023 on 120 days’ notice.
  • Development priorities included an Ovaprene pivotal Phase 3 study, topline results from the exploratory Phase 2b RESPOND study of Sildenafil Cream targeted for the second quarter of 2023, and progression of DARE-HRT1 toward Phase 3. These are forward-looking plans, not assured outcomes. Ovaprene’s Bayer license becomes effective only if Bayer elects to pay a further $20 million; Bayer retains discretion to terminate.
  • Key risks include clinical or regulatory failure and delays, reliance on collaborators and single-source manufacturers, difficulty raising capital and potential shareholder dilution, reimbursement and market-adoption uncertainty, intellectual-property and licensing risks, and competition. The filing reports that Ovaprene’s Phase 3 timing was delayed by FDA study-design considerations and clinical-supply delays.
  • Subsequent events: in March 2023, the company reported access to its Silicon Valley Bank accounts had been restored after the bank’s closure. It also disclosed a business-email-compromise fraud that misdirected approximately $0.4 million; it expected insurance to cover about $0.2 million and did not expect a material financial impact. The company terminated its two ATM sales agreements effective March 30, 2023. Warrants exercised in January and February 2023 generated approximately $1.3 million in gross proceeds.

Investor verification priorities

  • Confirm current unrestricted cash, grant-fund restrictions, cash burn, financing completed since filing, and the company’s latest liquidity and going-concern disclosures.
  • Verify XACIATO’s actual launch date, sales, pricing and reimbursement, Organon’s commercialization progress, and any milestone or royalty receipts.
  • Review final RESPOND results, the Ovaprene Phase 3 start and supply readiness, and subsequent DARE-HRT1 clinical and regulatory plans.
  • Assess financing terms and dilution, including subsequent share or warrant issuances and the status of a replacement ATM facility.
  • Check whether the reported fraud loss was recovered as expected and whether any material changes arose from the SVB disruption.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.